Positive
●
Invezz
●
3 months ago
uniQure (QURE) stock is ripping higher this morning after the biopharmaceutical firm announced a major regulatory breakthrough with the FDA for its Huntington's disease gene therapy AMT-130. As investors cheered the disclosure, QURE pushed past its key moving averages (MAs) – and its relative strength index (RSI) climbed into the mid-80s, indicating intense buying pressure.